Comparative Pharmacology
Head-to-head clinical analysis: ENOVID E versus OVRAL 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENOVID E versus OVRAL 28.
ENOVID-E vs OVRAL-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive. Suppresses gonadotropin release, inhibits ovulation, increases cervical mucus viscosity, and alters endometrial morphology.
Combination oral contraceptive: suppresses gonadotropin release via estrogen and progestin, inhibiting ovulation, thickening cervical mucus, and altering endometrial lining.
5 mg orally once daily for 20 days starting on day 5 of menstrual cycle
One tablet (norgestrel 0.3 mg, ethinyl estradiol 0.03 mg) orally once daily for 21 consecutive days, followed by 7 days of placebo.
None Documented
None Documented
Norethynodrel: 5-10 hours; mestranol: 2-5 hours (metabolized to ethinyl estradiol, half-life 10-20 hours). Steady-state reached in 5-7 days.
Ethinyl estradiol: terminal half-life 13-27 hours (mean ~17 hours); norgestrel: terminal half-life 11-45 hours (mean ~24 hours). Clinical context: steady-state reached within 5-7 days; accumulation minimal with daily dosing.
Renal (50-60% as metabolites, <1% unchanged); fecal (40-50%)
Renal: ~40% as metabolites; fecal: ~60% via biliary excretion, primarily as glucuronide and sulfate conjugates.
Category C
Category C
Oral Contraceptive
Oral Contraceptive